Wuxi AppTec Co Ltd Class A 603259
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 603259 is a good fit for your portfolio.
News
-
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
-
WuXi AppTec's Shares Fall After Downbeat Guidance
-
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat
-
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
-
WuXi AppTec Says It Left Washington Lobbying Group Voluntarily
-
WuXi Shares Fall as Washington Lobbying Group Cuts Ties
-
WuXi Companies' Shares Fall Amid Renewed U.S. Sanction Concerns
-
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions
Trading Information
- Previous Close Price
- CNY 44.57
- Day Range
- CNY 43.52–44.78
- 52-Week Range
- CNY 41.17–93.56
- Bid/Ask
- CNY 43.66 / CNY 43.67
- Market Cap
- CNY 128.10 Bil
- Volume/Avg
- 80.7 Mil / 98.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 12.37
- Price/Sales
- 3.21
- Dividend Yield (Trailing)
- 2.04%
- Dividend Yield (Forward)
- 2.04%
- Total Yield
- 2.04%
Company Profile
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, gene therapies, and testing services for medical devices. Its segments comprise WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It generates the majority of its revenue from the WuXi Chemistry segment. Its geographic areas are the PRC, USA, Europe, and the Rest of the world, in which it generates the majority of its revenue from the USA.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Large Core
- Total Number of Employees
- 41,116
- Website
- https://www.wuxiapptec.com
Comparables
Valuation
|
Metric
|
603259
|
ACRS
|
300685
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.37 | — | 33.57 |
Price/Book Value | 2.35 | 0.55 | 4.92 |
Price/Sales | 3.21 | 2.70 | 7.97 |
Price/Cash Flow | 9.77 | — | 27.66 |
Price/Earnings
603259
ACRS
300685
Financial Strength
|
Metric
|
603259
|
ACRS
|
300685
|
|---|---|---|---|
Quick Ratio | 1.57 | 3.86 | 13.42 |
Current Ratio | 2.06 | 4.16 | 13.97 |
Interest Coverage | 59.83 | — | 194.63 |
Quick Ratio
603259
ACRS
300685
Profitability
|
Metric
|
603259
|
ACRS
|
300685
|
|---|---|---|---|
Return on Assets (Normalized) | 14.02% | −38.26% | 11.25% |
Return on Equity (Normalized) | 19.29% | −50.08% | 12.34% |
Return on Invested Capital (Normalized) | 16.81% | −49.93% | 12.20% |
Return on Assets
603259
ACRS
300685
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Jhpxyjkmgg | Rgvs | $217.1 Bil | |
DHR
| Danaher Corp | Qmqxbssncb | Myxbvfn | $182.7 Bil | |
IQV
| IQVIA Holdings Inc | Gzrczqgy | Mqfvqd | $42.2 Bil | |
IDXX
| IDEXX Laboratories Inc | Pdnnldwlq | Pqddbg | $40.9 Bil | |
A
| Agilent Technologies Inc | Ssqjvkxxb | Sfnl | $40.2 Bil | |
MTD
| Mettler-Toledo International Inc | Lfchnbctn | Bnrrgmy | $26.3 Bil | |
ICLR
| Icon PLC | Hzfgbqdc | Xlzynp | $24.6 Bil | |
ILMN
| Illumina Inc | Jcpdwnlkc | Xtpvm | $19.6 Bil | |
WAT
| Waters Corp | Ffmvpbyhsb | Lbvr | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Tgdqwqtr | Hbxvhxz | $17.0 Bil |